Viatris | Jotup

Viatris Inc. and Kindeva Drug Delivery Announce FDA Tentative Approval of the First Abbreviated New Drug Application Generic Version of Symbicort® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol

Retrieved on:

Lunedì, Marzo 8, 2021

Health sciences, Health care, Drugs, Routes of administration, Viatris, Transdermal patch, Food and Drug Administration, Budesonide/formoterol, Transdermal, Nicotine replacement therapy

Viatris CEO Michael Goettler commented: "The FDA's tentative approval of generic Symbicort represents yet another significant milestone for Viatris in advancing access to treatment for respiratory patients.

Key Points:

Viatris CEO Michael Goettler commented: "The FDA's tentative approval of generic Symbicort represents yet another significant milestone for Viatris in advancing access to treatment for respiratory patients.
The FDA provided tentative approval at this time due to ongoing patent litigation.
Viatris and Kindeva are committed to bringing a generic Symbicort to market as soon as possible.
Kindeva focuses on complex drug programs, and its current offering spans inhalation drug delivery, transdermal drug delivery, microstructured transdermal systems (microsystems), and connected drug delivery.

Viatris Inc. to Hold Conference Call on Monday, Feb. 22, 2021, to Discuss 2021 Financial Guidance

Retrieved on:

Martedì, Febbraio 9, 2021

Viatris, Slide, REPLAY, Software, Companies

(NASDAQ: VTRS) today announcedthat it will host a conference call at8 a.m. ETonMonday, Feb. 22to discuss 2021 financial guidance.

Key Points:

(NASDAQ: VTRS) today announcedthat it will host a conference call at8 a.m. ETonMonday, Feb. 22to discuss 2021 financial guidance.
A slide presentation and replay of the webcast also will be available on the website.
As previously announced, Viatris will hold its inaugural Investor Day virtually on Monday, March 1, 2021.
Viatris undertakes no obligation to update these statements for revisions or changes after the date of this release other than as required by law.

Zendesk To Present At An Upcoming Investor Conference

Retrieved on:

Giovedì, Gennaio 28, 2021

Zendesk, Inc. (NYSE:ZEN) today announced its participation in an upcoming investor conference.

Key Points:

Zendesk, Inc. (NYSE:ZEN) today announced its participation in an upcoming investor conference.
Elena Gomez, Chief Financial Officer, and Marc Cabi, Senior Vice President of Investor Relations and Strategic Finance & Analytics, will virtually present at Goldman Sachs Technology and Internet Conference 2021 on Wednesday, February 10, 2021.
A live webcast of this presentation will be accessible by visiting Zendesks investor website at investor.zendesk.com.
Zendesk is a service-first CRM company that builds support, sales, and customer engagement software designed to foster better customer relationships.

FTC Approves Final Order Imposing Conditions on Combination of Pfizer Inc.’s Upjohn and Mylan N.V.

Retrieved on:

Giovedì, Gennaio 28, 2021

Pharmaceutical companies, Life sciences, Companies, Canonsburg, Pennsylvania, Mylan, Pfizer, Viatris, Upjohn, Pharmaceuticals policy, Generic drug, Heather Bresch

Following a public comment period, the Federal Trade Commission has approved a final ordersettling charges that the combination of the Upjohn division of pharmaceutical company Pfizer and Mylan N.V. would violate federal antitrust law.

Key Points:

Following a public comment period, the Federal Trade Commission has approved a final ordersettling charges that the combination of the Upjohn division of pharmaceutical company Pfizer and Mylan N.V. would violate federal antitrust law.
The proposed transaction contemplated that Pfizer Inc. would spin off its Upjohn divisionwhich includes Pfizers authorized generic business Greenstone, LLCand combine it with Mylan to form Viatris Inc.
The complaint, which was first announced in October 2020, alleged that the combination would likely harm current competition in seven generic drug markets and future competition in three generic drug markets.
The final order requires the parties to divest rights and assets in the seven current generic drug markets where harm was likely.

FTC Approves Final Order Imposing Conditions on Combination of Pfizer Inc.’s Upjohn and Mylan N.V.

Retrieved on:

Giovedì, Gennaio 28, 2021

Pharmaceutical companies, Life sciences, Companies, Canonsburg, Pennsylvania, Mylan, Pfizer, Viatris, Upjohn, Pharmaceuticals policy, Generic drug, Heather Bresch

Following a public comment period, the Federal Trade Commission has approved a final ordersettling charges that the combination of the Upjohn division of pharmaceutical company Pfizer and Mylan N.V. would violate federal antitrust law.

Key Points:

Following a public comment period, the Federal Trade Commission has approved a final ordersettling charges that the combination of the Upjohn division of pharmaceutical company Pfizer and Mylan N.V. would violate federal antitrust law.
The proposed transaction contemplated that Pfizer Inc. would spin off its Upjohn divisionwhich includes Pfizers authorized generic business Greenstone, LLCand combine it with Mylan to form Viatris Inc.
The complaint, which was first announced in October 2020, alleged that the combination would likely harm current competition in seven generic drug markets and future competition in three generic drug markets.
The final order requires the parties to divest rights and assets in the seven current generic drug markets where harm was likely.

Mylan Wins Summary Judgment in EpiPen® Litigation Brought by Sanofi

Retrieved on:

Venerdì, Dicembre 18, 2020

Companies, Pharmaceutical companies, Health care, Canonsburg, Pennsylvania, Mylan, Epinephrine autoinjector, Sanofi, Viatris, MYL

PITTSBURGH, Dec. 18, 2020 /PRNewswire/ --Viatris Inc.(NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas entered summary judgment in Mylan's favor in the lawsuit brought against it by Sanofi related to its EpiPen products.

Key Points:

PITTSBURGH, Dec. 18, 2020 /PRNewswire/ --Viatris Inc.(NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas entered summary judgment in Mylan's favor in the lawsuit brought against it by Sanofi related to its EpiPen products.
For the past three years, Sanofi, one of the world's largest pharmaceutical companies, has unjustly pursued money damages and attempted to blame Mylan for Sanofi's own failures in marketing Auvi-Q.
The Court's favorable judgment should put an end to this attempt by Sanofi to advance a false narrative against Mylan and to use the antitrust laws to punish, rather than promote, competition.
Mylan has given away more than 1 million EpiPen products to schools across America.

Viatris Inc. Announces Additional Details of Previously Disclosed Global Restructuring Initiative

Retrieved on:

Venerdì, Dicembre 11, 2020

Companies, Viatris, Mylan, Restructuring, Articles, Industries

(NASDAQ: VTRS) today announcedadditional details ofits previously disclosed multi-year global restructuring initiative.

Key Points:

(NASDAQ: VTRS) today announcedadditional details ofits previously disclosed multi-year global restructuring initiative.
Viatris' restructuring initiative incorporates and expands on the restructuring program announced by Mylan earlier this year as part of its business transformation efforts.
As a result, Viatris expects that up to 20% of its global workforce of approximately 45,000 may be impacted upon completion of the restructuring initiative.
The company will maintain an extensive overall employee base and global manufacturing network that aligns with its go-forward operations.

Viatris Inc. to Present at the J.P. Morgan 39th Annual Healthcare Conference January 14, 2021 and Will Host its Inaugural Investor Day March 1, 2021

Retrieved on:

Giovedì, Dicembre 10, 2020

Viatris, NASDAQ, Companies, Finance, Economy of the United States

(NASDAQ: VTRS) will present at the J.P. Morgan 39th Annual Healthcare Conference on Thursday, January 14, 2021.

Key Points:

(NASDAQ: VTRS) will present at the J.P. Morgan 39th Annual Healthcare Conference on Thursday, January 14, 2021.
Michael Goettler, chief executive officer, will make a formal presentation about the company at 7:30 a.m.
Investors and the general public are invited to listen to a live webcast of the presentation at investor.viatris.com .
Viatris also announced that it will hold its inaugural Investor Day virtually on Monday, March 1, 2021.